Targeting IL-17 and TH17 cells in chronic inflammation
The DOI matches its Crossref record; 169 of the 169 references it cites were found in a registry or an index.
Abstract
The key role of interleukin-17 (IL-17) and T helper 17 (T(H)17) cells in tissue inflammation, autoimmunity and host defence led to the experimental targeting of these molecules in mouse models of diseases as well as in clinical settings. Moreover, the demonstration that IL-17 and T(H)17 cells contribute to local and systemic aspects of disease pathogenesis, as well as the finding that the IL-17-T(H)17 cell pathway is regulated by IL-23, prompted the identification of inhibitors. These inhibitors include biotechnology products that target IL-23 as well as the leading member of the IL-17 family, IL-17A, and one of its receptors, IL-17 receptor A. Several clinical trials of these inhibitors are underway, and positive results have been obtained in psoriasis, rheumatoid arthritis and ankylosing spondylitis. This Review focuses on the current knowledge of the IL-17-T(H)17 cell pathway to better understand the positive as well as potential negative consequences of targeting them.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Abs against IL-17/IL-17RA are in clinical trials for other autoimmune conditions [55].”
From The Kallikrein-Kinin System: A Novel Mediator of IL-17-Driven Anti-Candida Immunity in the Kidney (2016) · cites this paper as [55]
Citations
Cites
Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., & Kuchroo, V. K. (2006) · Nature · doi:10.1038/nature04753 · Cited by 6,992
Harrington, L. E., Hatton, R. D., Mangan, P. R., Turner, H., Murphy, T. L., Murphy, K. M., & Weaver, C. T. (2005) · Nature Immunology · doi:10.1038/ni1254 · Cited by 4,742
A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17
Park, H., Li, Z., Yang, X. O., Chang, S. H., Nurieva, R., Wang, Y.-H., Wang, Y., Hood, L., Zhu, Z., Tian, Q., et al. (2005) · Nature Immunology · doi:10.1038/ni1261 · Cited by 4,265
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation
Langrish, C. L., Chen, Y., Blumenschein, W. M., Mattson, J., Basham, B., Sedgwick, J. D., McClanahan, T., Kastelein, R. A., & Cua, D. J. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041257 · Cited by 4,099
Veldhoen, M., Hocking, R. J., Atkins, C. J., Locksley, R. M., & Stockinger, B. (2006) · Immunity · doi:10.1016/j.immuni.2006.01.001 · Cited by 3,605
Transforming growth factor-β induces development of the TH17 lineage
Mangan, P. R., Harrington, L. E., O'Quinn, D. B., Helms, W. S., Bullard, D. C., Elson, C. O., Hatton, R. D., Wahl, S. M., Schoeb, T. R., & Weaver, C. T. (2006) · Nature · doi:10.1038/nature04754 · Cited by 3,087
Cua, D. J., Sherlock, J., Chen, Y., Murphy, C. A., Joyce, B., Seymour, B., Lucian, L., To, W., Kwan, S., Churakova, T., et al. (2003) · Nature · doi:10.1038/nature01355 · Cited by 2,906
Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis
Zheng, Y., Danilenko, D. M., Valdez, P., Kasman, I., Eastham-Anderson, J., Wu, J., & Ouyang, W. (2007) · Nature · doi:10.1038/nature05505 · Cited by 1,862
Aggarwal, S., Ghilardi, N., Xie, M.-H., de Sauvage, F. J., & Gurney, A. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m207577200 · Cited by 1,847
Lock, C., Hermans, G., Pedotti, R., Brendolan, A., Schadt, E., Garren, H., Langer-Gould, A., Strober, S., Cannella, B., Allard, J., et al. (2002) · Nature Medicine · doi:10.1038/nm0502-500 · Cited by 1,669
Research works printed but not linked: 1
- Baeten, D. et al. The anti-IL17A monoclonal antibody secukinumab (AIN457) showed good safety and efficacy in the treatment of active ankylosing spondylitis. Arthritis Rheum. 62, Abstract L3847 (2010).
Cited by
Interaction between microbiota and immunity in health and disease
Zheng, D., Liwinski, T., & Elinav, E. (2020) · Cell Research · doi:10.1038/s41422-020-0332-7 · Cited by 3,947
“Of these cells, the Th17 subset is intensely studied because of its ambiguous roles in both host protection and inflammatory disorders.(109) The intestine harbors functionally distinct Th17 cell populations and their inflammatory propensity is largely determined by distinct bacteria eliciting their differentiation.”
BackgroundZhang, C., Wu, Z., Li, J.-W., Zhao, H., & Wang, G.-Q. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105954 · Cited by 1,758
The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
O'Shea, J. J., Schwartz, D. M., Villarino, A. V., Gadina, M., McInnes, I. B., & Laurence, A. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-051113-024537 · Cited by 1,599
“IL-17 acts on broadly expressed receptors to increase the production and recruitment of neutrophils to sites of inflammation and is especially important for host defense against Staphylococcus aureus and fungal infections (8).”
BackgroundSieper, J., & Poddubnyy, D. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31591-4 · Cited by 1,333
Immunopathogenesis of Rheumatoid Arthritis
Firestein, G. S., & McInnes, I. B. (2017) · Immunity · doi:10.1016/j.immuni.2017.02.006 · Cited by 1,301
“Murine arthritis models strongly suggest a pivotal role for T helper 17 (Th17) cells (Miossec and Kolls, 2012; Lubberts, 2015).”
Immunomicrobial pathogenesis of periodontitis: keystones, pathobionts, and host response
Hajishengallis, G. (2014) · Trends in Immunology · doi:10.1016/j.it.2013.09.001 · Cited by 1,150
Th17 and regulatory T cell balance in autoimmune and inflammatory diseases
Noack, M., & Miossec, P. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.12.004 · Cited by 932
Self-citationGriffiths, C. E. M., Reich, K., Lebwohl, M., van de Kerkhof, P., Paul, C., Menter, A., Cameron, G. S., Erickson, J., Zhang, L., Secrest, R. J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60125-8 · Cited by 834
The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis
Blauvelt, A., & Chiricozzi, A. (2018) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-018-8702-3 · Cited by 789
IL-17 Signaling: The Yin and the Yang
Amatya, N., Garg, A. V., & Gaffen, S. L. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.01.006 · Cited by 785
“However, the efficacy of IL-17 blockade for other conditions has been less dramatic [7], though there are promising data from trials of ankylosing spondylitis and psoriatic arthritis [7, 12].”
BackgroundMacrophage heterogeneity in the context of rheumatoid arthritis
Udalova, I. A., Mantovani, A., & Feldmann, M. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.91 · Cited by 686
Cytokine networks in neuroinflammation
Becher, B., Spath, S., & Goverman, J. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.123 · Cited by 697
Evolving therapies for liver fibrosis
Schuppan, D., & Kim, Y. O. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66028 · Cited by 595
The Immunopathophysiology of Endometriosis
Symons, L. K., Miller, J. E., Kay, V. R., Marks, R. M., Liblik, K., Koti, M., & Tayade, C. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.07.004 · Cited by 567
“Several Phase I, II, and III clinical trials are being conducted targeting IL-17 or the IL-17 receptor in psoriasis, rheumatoid arthritis, Crohn’s disease, asthma, and multiple sclerosis [76].”
BackgroundTherapeutic opportunities of the IL-22–IL-22R1 system
Sabat, R., Ouyang, W., & Wolk, K. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4176 · Cited by 562
Choi, J., Park, J.-E., Tsagkogeorga, G., Yanagita, M., Koo, B.-K., Han, N., & Lee, J.-H. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2020.06.020 · Cited by 588
Periodontal Inflammation and Systemic Diseases: An Overview
Martínez-García, M., & Hernández-Lemus, E. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.709438 · Cited by 512
Interleukin-21: a double-edged sword with therapeutic potential
Spolski, R., & Leonard, W. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4296 · Cited by 548
IL-17 receptor–based signaling and implications for disease
Li, X., Bechara, R., Zhao, J., McGeachy, M. J., & Gaffen, S. L. (2019) · Nature Immunology · doi:10.1038/s41590-019-0514-y · Cited by 548
Current understanding of periodontal disease pathogenesis and targets for host‐modulation therapy
Hajishengallis, G., Chavakis, T., & Lambris, J. D. (2020) · Periodontology 2000 · doi:10.1111/prd.12331 · Cited by 502
Basic biology and role of interleukin‐17 in immunity and inflammation
Zenobia, C., & Hajishengallis, G. (2015) · Periodontology 2000 · doi:10.1111/prd.12083 · Cited by 470
Th17 Cell Pathway in Human Immunity: Lessons from Genetics and Therapeutic Interventions
Patel, D. D., & Kuchroo, V. K. (2015) · Immunity · doi:10.1016/j.immuni.2015.12.003 · Cited by 486
Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy
Wu, Y., Yi, M., Niu, M., Mei, Q., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01657-y · Cited by 458
“It is well known that IL-17 is the key cytokine produced by Th17 cells [140].”
BackgroundT H 2 and T H 17 inflammatory pathways are reciprocally regulated in asthma
Choy, D. F., Hart, K. M., Borthwick, L. A., Shikotra, A., Nagarkar, D. R., Siddiqui, S., Jia, G., Ohri, C. M., Doran, E., Vannella, K. M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aab3142 · Cited by 450
The IL-23-IL-17 axis in inflammatory arthritis
Lubberts, E. (2015) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.53 · Cited by 442
Current concepts in the pathogenesis of periodontitis: from symbiosis to dysbiosis
Abdulkareem, A. A., Al-Taweel, F. B., Al-Sharqi, A. J. B., Gul, S. S., Sha, A., & Chapple, I. L. C. (2023) · Journal of Oral Microbiology · doi:10.1080/20002297.2023.2197779 · Cited by 367
“In addition, neutrophils promote Th17 cells which represent an osteoclastogenic T-cell subset that has been linked to bone loss [159],”
BackgroundIL-17 in Chronic Inflammation: From Discovery to Targeting
Beringer, A., Noack, M., & Miossec, P. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.01.001 · Cited by 402
Self-citationEmerging cytokine networks in colorectal cancer
West, N. R., McCuaig, S., Franchini, F., & Powrie, F. (2015) · Nature Reviews Immunology · doi:10.1038/nri3896 · Cited by 396
Immune crosstalk in cancer progression and metastatic spread: a complex conversation
Garner, H., & de Visser, K. E. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0271-z · Cited by 395
Balić, A., Vlašić, D., Žužul, K., Marinović, B., & Bukvić Mokos, Z. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030741 · Cited by 400
“Systemic inflammatory state led by IL-23/IL-17 pathway, a central player in immune regulation, and the related Th17 cells seem to be the common denominator for all these comorbidities, as it is for many other chronic inflammatory diseases [114,115].”
BackgroundWu, J., Wei, Z., Cheng, P., Qian, C., Xu, F., Yang, Y., Wang, A., Chen, W., Sun, Z., & Lu, Y. (2020) · Theranostics · doi:10.7150/thno.43528 · Cited by 393
“Since IL-17 is mainly secreted by Th17 cells [20], closely related to colonic inflammation [21], we next examined Th17 cells in mouse mesenteric lymph nodes (MLN).”
BackgroundTargan, S. R., Feagan, B., Vermeire, S., Panaccione, R., Melmed, G. Y., Landers, C., Li, D., Russell, C., Newmark, R., Zhang, N., et al. (2016) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.298 · Cited by 383
Dutzan, N., Kajikawa, T., Abusleme, L., Greenwell-Wild, T., Zuazo, C. E., Ikeuchi, T., Brenchley, L., Abe, T., Hurabielle, C., Martin, D., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat0797 · Cited by 382
Sakornsakolpat, P., Prokopenko, D., Lamontagne, M., Reeve, N. F., Guyatt, A. L., Jackson, V. E., Shrine, N., Qiao, D., Bartz, T. M., Kim, D. K., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0342-2 · Cited by 384
Interleukin-17 and innate immunity in infections and chronic inflammation
Isailovic, N., Daigo, K., Mantovani, A., & Selmi, C. (2015) · Journal of Autoimmunity · doi:10.1016/j.jaut.2015.04.006 · Cited by 363
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity
Hailemichael, Y., Johnson, D. H., Abdel-Wahab, N., Foo, W. C., Bentebibel, S.-E., Daher, M., Haymaker, C., Wani, K., Saberian, C., Ogata, D., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.04.004 · Cited by 359
Hyperprogressive disease: recognizing a novel pattern to improve patient management
Champiat, S., Ferrara, R., Massard, C., Besse, B., Marabelle, A., Soria, J.-C., & Ferté, C. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0111-2 · Cited by 362
Targeting Th17 cells in autoimmune diseases
Yang, J., Sundrud, M. S., Skepner, J., & Yamagata, T. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.07.006 · Cited by 348
Breaking bad: Manipulation of the host response by Porphyromonas gingivalis
Hajishengallis, G., & Lamont, R. J. (2014) · European Journal of Immunology · doi:10.1002/eji.201344202 · Cited by 336
Effector T Cells in Multiple Sclerosis
Kaskow, B. J., & Baecher-Allan, C. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a029025 · Cited by 314
Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease
Coskun, M., Salem, M., Pedersen, J., & Nielsen, O. H. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2013.06.007 · Cited by 325
Contribution of Angiogenesis to Inflammation and Cancer
Aguilar-Cazares, D., Chavez-Dominguez, R., Carlos-Reyes, A., Lopez-Camarillo, C., Hernadez de la Cruz, O. N., & Lopez-Gonzalez, J. S. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01399 · Cited by 317
“Combination of IL-17 with other cytokines such as IL-6 and IL-8 contributes to the chronicity of inflammation (54, 55).”
BackgroundImmune Disorders in Hashimoto’s Thyroiditis: What Do We Know So Far?
Pyzik, A., Grywalska, E., Matyjaszek-Matuszek, B., & Roliński, J. (2015) · Journal of Immunology Research · doi:10.1155/2015/979167 · Cited by 305
Bispecific Antibodies: From Research to Clinical Application
Ma, J., Mo, Y., Tang, M., Shen, J., Qi, Y., Zhao, W., Huang, Y., Xu, Y., & Qian, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.626616 · Cited by 305
“Antibodies that use the DVD-Ig platform are ABT122 (IL-7×TNF-a), which is used to treat patients with rheumatoid arthritis (RA) who have experienced an inadequate response to methotrexate (47); and ABT165 (Delta-like ligand 4, DLL4×VEGF) which can effectively and significantly inhibit tumor growth in U87-MG human glio…”
BackgroundCytokines as Therapeutic Targets in Rheumatoid Arthritis and Other Inflammatory Diseases
Siebert, S., Tsoukas, A., Robertson, J., & McInnes, I. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009639 · Cited by 307
“making it a valuable target for therapeutic manipulation (Miossec and Kolls, 2012).”
BackgroundSelected cytokine pathways in rheumatoid arthritis
Noack, M., & Miossec, P. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-017-0619-z · Cited by 303
Self-citationIL-17–Mediated Immunity to the Opportunistic Fungal Pathogen Candida albicans
Conti, H. R., & Gaffen, S. L. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500909 · Cited by 301
Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19
Luo, W., Li, Y.-X., Jiang, L.-J., Chen, Q., Wang, T., & Ye, D.-W. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.06.007 · Cited by 296
“Moreover, immature T helper (Th0) cells can differentiate into Th17 mainly in the presence of IL-6, a cytokine involved in CRS in COVID-19 that also employs JAK2 to activate downstream signal (Figure 1) [43].”
The dual roles of cytokines in Alzheimer’s disease: update on interleukins, TNF-α, TGF-β and IFN-γ
Zheng, C., Zhou, X.-W., & Wang, J.-Z. (2016) · Translational Neurodegeneration · doi:10.1186/s40035-016-0054-4 · Cited by 292
“IL-17 [162] \ \ \ \ \ \ \ \ \”
Roles of XBP1s in Transcriptional Regulation of Target Genes
Park, S.-M., Kang, T.-I., & So, J.-S. (2021) · Biomedicines · doi:10.3390/biomedicines9070791 · Cited by 258
Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies
Ahluwalia, B., Moraes, L., Magnusson, M. K., & Öhman, L. (2018) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2018.1447597 · Cited by 241
“However, this Th1/Th2 characterization has been revised after the discovery of Th17 cells and their key role in inflammatory conditions such as IBD [75].”
BackgroundHajishengallis, G., & Korostoff, J. M. (2017) · Periodontology 2000 · doi:10.1111/prd.12181 · Cited by 241
“Moreover, interleukin-17 can mediate destruction of connective tissue by inducing the expression of matrix metalloproteinases in fibroblasts (178) (Fig.”
BackgroundUsing EAE to better understand principles of immune function and autoimmune pathology
Rangachari, M., & Kuchroo, V. K. (2013) · Journal of Autoimmunity · doi:10.1016/j.jaut.2013.06.008 · Cited by 246
“Excitingly, data suggest that it can reduce the frequency of gadoliniumenhancing lesions seen on MRI scans of RRMS brains (AIN457 MS Study group, presented at ECTRIMS 2012).”
BackgroundArmstrong, A. W., Blauvelt, A., Callis Duffin, K., Huang, Y.-H., Savage, L. J., Guo, L., & Merola, J. F. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00630-5 · Cited by 200
Hochrein, S. M., Wu, H., Eckstein, M., Arrigoni, L., Herman, J. S., Schumacher, F., Gerecke, C., Rosenfeldt, M., Grün, D., Kleuser, B., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.02.015 · Cited by 246
Ip, W. K. E., & Medzhitov, R. (2015) · Nature Communications · doi:10.1038/ncomms7931 · Cited by 244
“Th17 response has been implicated in the pathogenesis of inflammation and autoimmunity in humans and mice 40 .”
Review: The Interleukin‐23/Interleukin‐17 Axis in Spondyloarthritis Pathogenesis: Th17 and Beyond
Smith, J. A., & Colbert, R. A. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38291 · Cited by 243
“Recognition of the importance of these pathways has spawned the development of biologic agents and small molecules that offer unique opportunities to advance the treatment of several immune-mediated diseases (11,118,119).”
BackgroundInterleukin-17 in chronic inflammatory neurological diseases
Milovanovic, J., Arsenijevic, A., Stojanovic, B., Kanjevac, T., Arsenijevic, D., Radosavljevic, G., Milovanovic, M., & Arsenijevic, N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00947 · Cited by 250
“Positive effects of IL-17 blockade have been shown in clinical trials of ankylosing spondylitis and psoriatic arthritis (12).”
BackgroundMcGinley, A. M., Sutton, C. E., Edwards, S. C., Leane, C. M., DeCourcey, J., Teijeiro, A., Hamilton, J. A., Boon, L., Djouder, N., & Mills, K. H. G. (2020) · Immunity · doi:10.1016/j.immuni.2020.01.002 · Cited by 248
“There is overwhelming evidence that Th17 cells and gdT17 cells play a pathogenic role in numerous autoimmune diseases, including psoriasis, MS, and rheumatoid arthritis (Jones et al., 2012; Mills, 2011; Miossec and Kolls, 2012).”
BackgroundMicrobiome Dependent Regulation of Tregs and Th17 Cells in Mucosa
Pandiyan, P., Bhaskaran, N., Zou, M., Schneider, E., Jayaraman, S., & Huehn, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00426 · Cited by 236
T Cells in Osteoarthritis: Alterations and Beyond
Li, Y.-S., Luo, W., Zhu, S.-A., & Lei, G.-H. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00356 · Cited by 223
Systemic immune mechanisms in atopic dermatitis and psoriasis with implications for treatment
Guttman‐Yassky, E., Krueger, J. G., & Lebwohl, M. G. (2018) · Experimental Dermatology · doi:10.1111/exd.13336 · Cited by 225
Lee, S.-Y., Lee, S. H., Yang, E.-J., Kim, E.-K., Kim, J.-K., Shin, D.-Y., & Cho, M.-L. (2015) · PLOS ONE · doi:10.1371/journal.pone.0135858 · Cited by 225
“Th17 cells that produce IL-17 induce inflammation, but Treg cells expressing FOXP3 exert anti-inflammatory activity [32,33].”
BackgroundThe Concise Guide to PHARMACOLOGY 2013/14: Catalytic Receptors
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12449 · Cited by 221
Th17 Cells in Autoimmune and Infectious Diseases
Zambrano-Zaragoza, J. F., Romo-Martínez, E. J., Durán-Avelar, M. D. J., García-Magallanes, N., & Vibanco-Pérez, N. (2014) · International Journal of Inflammation · doi:10.1155/2014/651503 · Cited by 209
Verma, A. H., Richardson, J. P., Zhou, C., Coleman, B. M., Moyes, D. L., Ho, J., Huppler, A. R., Ramani, K., McGeachy, M. J., Mufazalov, I. A., et al. (2017) · Science Immunology · doi:10.1126/sciimmunol.aam8834 · Cited by 218
Melatonin signaling in T cells: Functions and applications
Ren, W., Liu, G., Chen, S., Yin, J., Wang, J., Tan, B., Wu, G., Bazer, F. W., Peng, Y., Li, T., et al. (2017) · Journal of Pineal Research · doi:10.1111/jpi.12394 · Cited by 209
Rheumatoid arthritis: pathogenesis and therapeutic advances
Gao, Y., Zhang, Y., & Liu, X. (2024) · MedComm · doi:10.1002/mco2.509 · Cited by 188
IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications
von Stebut, E., Boehncke, W.-H., Ghoreschi, K., Gori, T., Kaya, Z., Thaci, D., & Schäffler, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03096 · Cited by 199
“Importantly, targeting IL-17A is also effective in psoriatic arthritis, demonstrating that the psoriatic inflammation at distant sites also depends on the action of IL-17A (52).”
BackgroundAhn, S. H., Edwards, A. K., Singh, S. S., Young, S. L., Lessey, B. A., & Tayade, C. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1501138 · Cited by 200
“Emerging evidences from cancer and autoimmune literature suggest that IL-17A contributes to the neoangiogenesis and perpetuates inflammatory responses (25, 33), but there are few reports investigating the role of IL-17A in the pathogenesis of endometriosis.”
BackgroundReich, K., Papp, K. A., Matheson, R. T., Tu, J. H., Bissonnette, R., Bourcier, M., Gratton, D., Kunynetz, R. A., Poulin, Y., Rosoph, L. A., et al. (2015) · Experimental Dermatology · doi:10.1111/exd.12710 · Cited by 204
Dendritic cell derived exosomes loaded neoantigens for personalized cancer immunotherapies
Li, J., Li, J., Peng, Y., Du, Y., Yang, Z., & Qi, X. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.11.053 · Cited by 201
New developments in neutrophil biology and periodontitis
Hajishengallis, G. (2020) · Periodontology 2000 · doi:10.1111/prd.12313 · Cited by 198
Akbay, E. A., Koyama, S., Liu, Y., Dries, R., Bufe, L. E., Silkes, M., Alam, M. M., Magee, D. M., Jones, R., Jinushi, M., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.04.017 · Cited by 198
“IL-17 is an early proinflammatory cytokine that is responsible for initiating the inflammatory response by inducing the production of several other cytokines in the target cells.(44) To understand how IL-17 affects the cytokine milieu in lungs, we measured the levels of cytokines with an ELISA.”
InfluentialZhang, J., Wang, D., Wang, L., Wang, S., Roden, A. C., Zhao, H., Li, X., Prakash, Y. S., Matteson, E. L., Tschumperlin, D. J., et al. (2019) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00301.2018 · Cited by 194
“The discovery of IL-17 cytokines as important mediators of asthma pathogenesis provided preclinical rationale that led to several clinical trials involving IL-17 inhibitors (3, 6, 40, 43).”
BackgroundMaresin 1 improves the Treg/Th17 imbalance in rheumatoid arthritis through miR-21
Jin, S., Chen, H., Li, Y., Zhong, H., Sun, W., Wang, J., Zhang, T., Ma, J., Yan, S., Zhang, J., et al. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-213511 · Cited by 195
Chen, X., Bi, M., Yang, J., Cai, J., Zhang, H., Zhu, Y., Zheng, Y., Liu, Q., Shi, G., & Zhang, Z. (2022) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2021.126704 · Cited by 191
Propionibacterium acnes Promotes Th17 and Th17/Th1 Responses in Acne Patients
Kistowska, M., Meier, B., Proust, T., Feldmeyer, L., Cozzio, A., Kuendig, T., Contassot, E., & French, L. E. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.290 · Cited by 185
van Hamburg, J. P., & Tas, S. W. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2017.12.006 · Cited by 186
IL‐17: overview and role in oral immunity and microbiome
Abusleme, L., & Moutsopoulos, N. (2017) · Oral Diseases · doi:10.1111/odi.12598 · Cited by 183
“IL-17 has a well-recognized role in immune surveillance at mucosal and barrier surfaces (Miossec & Kolls, 2012, Song et al., 2016) but also has been increasingly implicated as a driver of immunopathology in settings of autoimmunity and chronic inflammation (Gaffen et al., 2014).”
InfluentialInflammation‐related cytokines in oral lichen planus: an overview
Lu, R., Zhang, J., Sun, W., Du, G., & Zhou, G. (2015) · Journal of Oral Pathology & Medicine · doi:10.1111/jop.12142 · Cited by 184
Interleukin-17 in human inflammatory diseases
Shabgah, A. G., Fattahi, E., & Shahneh, F. Z. (2014) · Advances in Dermatology and Allergology · doi:10.5114/pdia.2014.40954 · Cited by 174
“Th17 cells as a pleiotropic cytokine can trigger an acute inflammatory response that is dominated by recruitment of granulocyte lineage, especially neutrophils against extracellular bacteria and some fungi [2].”
BackgroundRobert, M., & Miossec, P. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2018.00364 · Cited by 165
“IL-17A, IL-17F, and IL-17A/F bind the same receptor composed of IL-17RA and IL17RC subunits (27).”
BackgroundSelf-citationIL-17 drives psoriatic inflammation via distinct, target cell-specific mechanisms
Ha, H.-L., Wang, H., Pisitkun, P., Kim, J.-C., Tassi, I., Tang, W., Morasso, M. I., Udey, M. C., & Siebenlist, U. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1400513111 · Cited by 171
Vogelpoel, L. T. C., Hansen, I. S., Rispens, T., Muller, F. J. M., van Capel, T. M. M., Turina, M. C., Vos, J. B., Baeten, D. L. P., Kapsenberg, M. L., de Jong, E. C., et al. (2014) · Nature Communications · doi:10.1038/ncomms6444 · Cited by 175
IL-17A as an Inducer for Th2 Immune Responses in Murine Atopic Dermatitis Models
Nakajima, S., Kitoh, A., Egawa, G., Natsuaki, Y., Nakamizo, S., Moniaga, C. S., Otsuka, A., Honda, T., Hanakawa, S., Amano, W., et al. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.51 · Cited by 169
“Consistently, the IL-17A-Th17 pathway is a good therapeutic target of psoriasis (Miossec and Kolls, 2012).”
BackgroundModulators of the Nuclear Receptor Retinoic Acid Receptor-Related Orphan Receptor-γ (RORγ or RORc)
Fauber, B. P., & Magnuson, S. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401901d · Cited by 165
Yi, B., Titze, J., Rykova, M., Feuerecker, M., Vassilieva, G., Nichiporuk, I., Schelling, G., Morukov, B., & Choukèr, A. (2015) · Translational Research · doi:10.1016/j.trsl.2014.11.007 · Cited by 166
Cui, Z., Wang, P., & Gao, W. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1517154 · Cited by 187
Letko, E., Yeh, S., Foster, C. S., Pleyer, U., Brigell, M., & Grosskreutz, C. L. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2014.12.033 · Cited by 166
“Interleukin (IL)-17A, which is produced by T-helper (Th) 17 and other immune cells, is one of the major proinflammatory cytokines in immunoinflammatory disorders.(11) Circulating Th17 cell levels are elevated during active uveitis and reduced following effective treatment.”
BackgroundIL-19 Is a Component of the Pathogenetic IL-23/IL-17 Cascade in Psoriasis
Witte, E., Kokolakis, G., Witte, K., Philipp, S., Doecke, W.-D., Babel, N., Wittig, B. M., Warszawska, K., Kurek, A., Erdmann-Keding, M., et al. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.308 · Cited by 164
“Moreover, anti-p40 and the recent IL-17 system– targeting therapies are very effective in psoriasis (Leonardi et al., 2008; Papp et al., 2008; Miossec and Kolls, 2012).”
BackgroundTumor-Elicited Inflammation and Colorectal Cancer
(2015) · Advances in Cancer Research · doi:10.1016/bs.acr.2015.04.014 · Cited by 161
Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease
Hohenberger, M., Cardwell, L. A., Oussedik, E., & Feldman, S. R. (2018) · Journal of Dermatological Treatment · doi:10.1080/09546634.2017.1329511 · Cited by 165
“The six IL-17 types include IL-17 A through IL-17 F (1).”
BackgroundLuo, H., Liu, H.-Z., Zhang, W.-W., Matsuda, M., Lv, N., Chen, G., Xu, Z.-Z., & Zhang, Y.-Q. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.085 · Cited by 162
“IL-17, referred to as IL-17A in literature, is a proinflammatory cytokine produced by Th17 cells (Miossec and Kolls, 2012; Korn et al., 2009).”
BackgroundJabaudon, M., Blondonnet, R., Roszyk, L., Bouvier, D., Audard, J., Clairefond, G., Fournier, M., Marceau, G., Déchelotte, P., Pereira, B., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201501-0020oc · Cited by 162
Proinflammatory Pathways in the Pathogenesis of Asthma
Peebles, R. S., & Aronica, M. A. (2019) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2018.10.014 · Cited by 179
Endothelial cells: From innocent bystanders to active participants in immune responses
Al-Soudi, A., Kaaij, M. H., & Tas, S. W. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.07.008 · Cited by 163
“Preclinical research has demonstrated that neutralization of IL-17 reduced disease severity and joint destruction [137].”
BackgroundTranslational and clinical advances in JAK-STAT biology: The present and future of jakinibs
Gadina, M., Johnson, C., Schwartz, D., Bonelli, M., Hasni, S., Kanno, Y., Changelian, P., Laurence, A., & O’Shea, J. J. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.5ri0218-084r · Cited by 159
Ashrafizadeh, M., Delfi, M., Hashemi, F., Zabolian, A., Saleki, H., Bagherian, M., Azami, N., Farahani, M. V., Sharifzadeh, S. O., Hamzehlou, S., et al. (2021) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2021.117809 · Cited by 160
T2-“Low” Asthma: Overview and Management Strategies
Fitzpatrick, A. M., Chipps, B. E., Holguín, F., & Woodruff, P. G. (2020) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2019.11.006 · Cited by 170
Metadata
- Authors
- Miossec, P., & Kolls, J. K.
- Affiliations
- Lyon 1 Université (FR)
- University of Pittsburgh (US)
- Corresponding author
- Miossec, Pierre
- Kolls, Jay K.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2012-10
- Volume
- 11
- Issue
- 10
- Pages
- 763-776
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2022917731
- Cited by
- 1,414
- References
- 169
- Citations by year
- 2026: 74 · 2025: 104 · 2024: 137 · 2023: 101 · 2022: 121 · 2021: 129 · 2020: 97 · 2019: 91 · 2018: 67 · 2017: 114 · 2016: 100 · 2015: 109 · 2014: 97 · 2013: 72 · 2012: 1
- FWCI
- 8.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Institut Universitaire de France
- Institut Mérieux
- National Heart, Lung, and Blood Institute (R37HL079142)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Keywords
- IL-17, Th17 cells, IL-17 inhibitors, IL-23, IL-17 receptor A, psoriasis, rheumatoid arthritis, ankylosing spondylitis, chronic inflammation, autoimmunity, biologic therapy, IL-17A
- MeSH terms
- Animals, Chronic Disease, Humans, Inflammation, Drug Delivery Systems, Interleukin-17, Receptors, Interleukin-17, Th17 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.